Men with metastatic castration-resistant prostate cancer and symptomatic bone metastases had longer survival times when they received radium-223 as first-line therapy compared with those who received the drug as third-line therapy.
Researchers suggest appropriate monitoring and use of standard treatment algorithms to identify and treat toxic effects after a rechallenge after irAEs in patients receiving ICI therapy.
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic.
The authors of new review say the results of the JCOG0401 trial suggest that standard hormonal therapy alone vs salvage radiotherapy is not an appropriate management strategy for recurrence after radical prostatectomy.
Although some patients with cancer are at higher risk of developing severe disease should they become infected, these experts suggest the precautions being given to the general population are sufficient — at least for now.
